[go: up one dir, main page]

AR039827A1 - Metodo para tratar la esclerosis multiple - Google Patents

Metodo para tratar la esclerosis multiple

Info

Publication number
AR039827A1
AR039827A1 ARP030101736A ARP030101736A AR039827A1 AR 039827 A1 AR039827 A1 AR 039827A1 AR P030101736 A ARP030101736 A AR P030101736A AR P030101736 A ARP030101736 A AR P030101736A AR 039827 A1 AR039827 A1 AR 039827A1
Authority
AR
Argentina
Prior art keywords
multiple sclerosis
treat multiple
treat
dexrazoxane
anthracycline
Prior art date
Application number
ARP030101736A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR039827A1 publication Critical patent/AR039827A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de una antraciclina, tal como la doxorrubicina, en forma aislada o en combinación con un agente protector, tal como el dexrazoxano, para el tratamiento de la esclerosis múltiple.
ARP030101736A 2002-05-21 2003-05-19 Metodo para tratar la esclerosis multiple AR039827A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38215902P 2002-05-21 2002-05-21

Publications (1)

Publication Number Publication Date
AR039827A1 true AR039827A1 (es) 2005-03-02

Family

ID=29584367

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101736A AR039827A1 (es) 2002-05-21 2003-05-19 Metodo para tratar la esclerosis multiple

Country Status (5)

Country Link
US (1) US20040038904A1 (es)
AR (1) AR039827A1 (es)
AU (1) AU2003237199A1 (es)
TW (1) TW200405814A (es)
WO (1) WO2003099296A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
PL2801355T3 (pl) * 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4257063A (en) * 1979-03-23 1981-03-17 Ham Industries, Inc. Video monitoring system and method
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
GB2172594B (en) * 1985-03-22 1988-06-08 Erba Farmitalia New morpholino derivatives of daunorubicin and doxorubicin
US4617319A (en) * 1985-06-13 1986-10-14 American Cyanamid Company Method of treating multiple sclerosis
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
US5196522A (en) * 1990-11-01 1993-03-23 Board Of Regents, The University Of Texas System Anthracycline analogues bearing latent alkylating substituents
ES2131819T3 (es) * 1994-03-11 1999-08-01 Zaidan Hojin Biseibutsu Derivados de antraciclina que contienen unidades de azucar trifluorometiladas.
IT1272234B (it) * 1994-05-02 1997-06-16 Consiglio Nazionale Ricerche Derivati glutationici delle antracicline e procedimento per ottenerli.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
EP0751144B1 (en) * 1995-06-27 2004-10-06 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
US8883856B2 (en) * 2000-02-28 2014-11-11 John Jackson Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors

Also Published As

Publication number Publication date
WO2003099296A1 (en) 2003-12-04
US20040038904A1 (en) 2004-02-26
TW200405814A (en) 2004-04-16
AU2003237199A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
PA8493401A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
CL2004000927A1 (es) Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.
AR050616A1 (es) Composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos.
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
MX364708B (es) Formulaciones y metodos para tratar la rinosinusitis.
WO2006006172A3 (en) Use of anti-amyloid agents for treating and typing pathogen infections
ECSP066378A (es) "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo"
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
IT1318425B1 (it) Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
AR030476A1 (es) Proteccion de las fibras queratinosas mediante el uso de ceramidas y/o glicoceramidas
AR039827A1 (es) Metodo para tratar la esclerosis multiple
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
TW200730190A (en) New combination to treat liver fibrosis
AR039948A1 (es) Metodo mejorado para el tratamiento de queso desmenuzado con un compuesto antihongo de polieno
WO2004031144A3 (en) Use of caspase inhibitors as therapeutic agent against radiation-induced injury

Legal Events

Date Code Title Description
FA Abandonment or withdrawal